Reduction of Coronavirus Burden With Mass Azithromycin Distribution

Clin Infect Dis. 2020 Nov 19;71(16):2282-2284. doi: 10.1093/cid/ciaa606.

Abstract

We evaluated the potential antiviral effects of azithromycin on the nasopharyngeal virome of Nigerien children who had received multiple rounds of mass drug administration. We found that the respiratory burden of non-severe acute respiratory syndrome coronaviruses was decreased with azithromycin distributions. Clinical Trials Registration. NCT02047981.

Keywords: Niger; azithromycin; children; coronavirus; virome.

Publication types

  • Clinical Trial, Phase IV
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use*
  • Azithromycin / administration & dosage
  • Azithromycin / therapeutic use*
  • Child, Preschool
  • Coronavirus / drug effects
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / mortality
  • Humans
  • Infant
  • Infant, Newborn
  • Mass Drug Administration*
  • Nasopharynx / virology*
  • Nigeria / epidemiology
  • Viral Load / drug effects*

Substances

  • Antiviral Agents
  • Azithromycin

Associated data

  • ClinicalTrials.gov/NCT02047981